Powered by Blogger.

Monday, 25 July 2016

Immunoglobulin demand to drive Global Plasma Protein Therapeutics Market

Transparency Market Research has published a new market report titled, “Global Plasma Protein Therapeutics Market: (Product Type – Coagulation Factors, Immunoglobulins, Albumin, C1-esterase Inhibitors, Alpha-1 Antitrypsin, and Others; Application: Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024.” According to the report, the global plasma protein therapeutics market was valued at US$ 18.5 Bn in 2015 and is projected to reach US$ 31.8 Bn by 2024.


Plasma protein are blood-derived medicines used in wide therapeutic areas. Life threatening diseases such as chronic lymphocytic leukemia, multiple myeloma, congenital AIDS, and hemophilia are treated with plasma-derived proteins. Market related factors such as growing use of immunoglobulins in primary immunodeficiency, and wide opportunities for human albumin in treatment of burns, shock and blood loss and also as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment. Other factors such as growing demand for plasma protein therapeutics owing to increasing development in new indications, additional application in existing indications, innovative solutions for safe and efficient plasma collection, better access to medicines in emerging markets, and new plasma-derived therapies drive the plasma protein therapeutics market.

Geographically, the global plasma protein therapeutics market has been segmented into the following regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America accounted for the largest share of 40.7% of the global plasma protein therapeutics market in 2015. Intravenous immunoglobulin (IVIG) was the largest segment of the market primarily due to increasing usage in new indications, new researches, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive PIDD treatment through IVIG. The plasma protein therapeutics market in North America will be further fueled by the increasing usage of immunoglobulins and C1 esterase inhibitors segment during the forecast period.

Europe was the second largest market for plasma protein therapeutics in 2015. This is attributed to high rate of plasma donation and growing demand for plasma protein in increasing number of indications. The intravenous immunoglobulin segment in Europe is expected to expand at an impressive CAGR during the forecast period due to increase in the number of patients with bleeding disorders and growing number of chronic inflammatory demyelinating polyneuropathy (CIPD) cases. Europe has experienced a surge in the amount of plasma collected and processed, which nearly doubled in the last decade. The immunoglobulin market continues to grow due to the increase in the number of clinical indications for IG. Germany was the leading market for plasma protein therapeutics in Europe, accounting for one-third share in 2015, followed by France, the U.K., Italy, and Spain. In terms of volume, Sweden was the largest market for plasma protein, followed by France, Spain, Italy, Switzerland, the U.K. and Germany.

Asia Pacific is projected to be the most attractive market for plasma protein therapeutics during the forecast period. The market in the region is anticipated to expand at the highest CAGR of 8.1% from 2016 to 2024. This is due to strong demand for immunoglobulin and albumin, improving health care facilities, increasing health care expenditure, and growing public awareness. China dominated the plasma protein therapeutics market in Asia Pacific. China imports 56% of its albumin supply to alleviate shortage and to decrease the demand-supply gap. Hence, albumin is projected to be the fastest growing segment in Asia Pacific. Other factors such as economic development in emerging economies such as India and China, where increase in health care expenditure and growing public awareness about immunodeficiency disorders would help the region to prevail as the most attractive market. Growing demand for IVIG in replacing absent antibodies in immune failure and treating immune deficiency, and other unmet medical needs is likely to propel the market in Asia Pacific.

Latin America is one of the largest economic regions of the future. Strong sales and market growth are expected over the medium term due to new marketing approvals for immunoglobulin and improved diagnosis rate of immunodeficiency. Companies are strengthening their regional presence in Latin America due to increasing product demand and growth opportunity in the region. Brazil is the leading market for plasma protein therapeutics in Latin America, followed by Mexico.

Key players in the global plasma protein therapeutics market are Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics. Baxalta (acquired by Shire plc), Grifols, and CSL Behring are likely to average 7% plasma sales growth between them over the next five years.

Saturday, 23 July 2016

Prostate Cancer Treatment to Revolutionize Standard of Care and Multiple Treatment Options

Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic cancer.


Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and Xofigo (Bayer Healthcare Pharmaceutical, Inc.). The prostate cancer therapeutics market is slated to increasing rapidly in the near future owing to promising drugs in the pipeline. These drugs are expected to drive the market during the forecast period from 2015 to 2023. In 2013, Johnson & Johnson acquired Aragon Pharmaceuticals that has second generation androgen receptor signaling inhibitor (ARN-509), a highly potential drug for treatment of castration resistant prostate cancer. This acquisition is seen as a strategic move by Johnson & Johnson to mitigate the expected slowing of Zytiga sales.

Zytiga, launched in 2011, clocked sales of over USD 1 billion in 2012 and works by targeting the enzyme CYP17A1 responsible for androgen production. The drug is expected to lose its patent protection in 2016. Moreover, Zytiga is facing stiff competition from Xtandi (Astellas Pharma, Inc. / Medivation, Inc.). The Astellas’ drug has already matched the sales of Zytiga and is rapidly moving further upstream as the patients are using treatment for long period and urologists continuing to adopt the drug. High prices of newer drugs and uncertain reimbursement policies will be restraining the market to some extent. However, the growing awareness about prostate cancer, rapid urbanization, and government efforts to fund cancer treatment will drive the market during the forecast period from 2015 to 2023.

On the basis of geography, the global prostate cancer therapeutics market can be segmented into four major regions, namely, North America, Europe, Asia Pacific, and Rest of the world. American men have highest rates of prostate cancer followed the European males. It is estimated that more than 230,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. In U.K., more than 40,000 new cases are registered having prostate cancer, and about 11,000 deaths occur annually. Therefore, the global prostate cancer therapeutics market has been traditionally dominated by North America Asia region ranks lowest in terms of rate of prostate cancer.

Some of the key players in this market are Johnson & Johnson, AstraZeneca plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc.

Tuesday, 5 July 2016

Learning Disability Treatment Market Leads by North America and Europe

A new market research report by Transparency Market Research, titled “Learning Disability Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” is a detailed evaluation that aids in recognizing the major unmet requirements in the market from 2014 to 2020. The prime developments poised to take place in the learning disability treatment market in the coming years have also been elaborated under this study. 


The current competition within this market coupled with an analysis on the competitors in the market is also a key part of this study. An insightful review on the key industry challenges, drivers, challenges, restraints, and trends is also a key part covered under this study. 

Learning disability is a term used for describing particular types of learning problems. This kind of disability can result in a person having trouble in learning and utilizing certain skills. The disorder occurs at an early age and is usually detected at 5 years of age. In this kind of disability, the brain of the patient is unable to store, receive, and respond to information. It isn’t a single disorder but a group of disorders that may include dyscalculia, dyslexia, dysgraphia, attention-deficit hyperactivity disorder (ADHD), dyspraxia, visual and auditory processing disorders. The common skills affected are listening, reading, speaking, writing, and reasoning. 

There are a number of learning disability therapies introduced globally. These are solution-focused counseling, cognitive behavioral therapy, and social skill groups to help children with learning disabilities. Due to the unknown cause of these disabilities, there are as of now no medicines to provide a core treatment for learning disabilities. 

However, some medicines are still being prescribed for the management and treatment of ADHD in patients. There are three major categories in which these medicines can be segmented, namely non-stimulants, stimulants, and other medicines. Of these, stimulants refer to psychoactive drugs focused on bringing temporary improvements in either physical or mental actions or both. Stimulants are the most commonly utilized and the best studied medicines so far for the treatment of ADHD within the market for learning disability treatment. 

Among the commonly utilized stimulants are: Methylphenidate (ritalin, concerta), dexmethylphenidate (focalin), amphetamine/dextroamphetamine (adderall, dexedrine, dextrostat), lisdexamfetamine (vyvanse). The other medicines utilized for learning disability treatment are antidepressants – bupropion (wellbutrin), tricyclics – imipramine (tofranil), nortriptyline (pamelor, aventyl), desipramine (norpramin), and alpha-2 agonists – clondine (catapres), guanfacine (tenex).

Geographically, Europe and North America are currently leading the global learning disability treatment market owing to the rising count of medications for ADHD and soaring count of schools for the children suffering from learning disabilities. On the other hand, Asia Pacific is also a rapidly developing market for learning disability treatment due to the increasing initiatives taken by governments for establishing special schools within this region.

Forest Laboratories, Inc., Pfizer, Inc., Novartis AG, Shire Plc., and Eli Lilly and Company, among others are the major players in the market, as per this study.

Full Research Report on Global Learning Disability Treatment Market:
http://www.transparencymarketresearch.com/learning-disability-treatment.html

Friday, 20 May 2016

Demand from North America Driving Global Medical Specialty Bags Market to US$7.6 bn by 2020

A new Transparency Market Research report states that the global medical specialty bags market pegged at US$5.4 bn in 2013 is predicted to reach US$7.6 bn by 2020 by expanding at a CAGR of 5.20% from 2014 to 2020. The title of the report is “Medical Specialty Bags Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”



Medical specialty bags are utilized in preventing, assisting, and treating numerous types of disorders such as cancer, ostomy, ophthalmic, and ophthalmic diseases. They are also utilized for laparoscopic surgical procedures and urinary surgical procedures, among others. The demand for surgeries is on the rise owing to the increasing occurrence of chronic diseases and the growing count of accidents, thus fuelling the demand for medical specialty bags. Medical specialty bags are extensively used within healthcare institutions and hospitals.
As per the report, the increasing count of hospitals in developing economies has boosted the market for medical specialty bags. In addition, the swiftly increasing aging population is a key factor impacting the market positively. Furthermore, the supportive reimbursement policies have encouraged the adoption of expensive treatments amongst patients, driving the growth of the market. The flexibility in FDA approval norms in case of 510k exempted class I devices is also a chief factor augmenting the growth of the market for medical specialty bags. Additionally, the improvement of the healthcare sector in developing nations has raised the count of healthcare procedures, thus propelling the development of the market. The soaring count of chronic diseases globally has also resulted in the increased demand for medical specialty bags. On the other hand, the absence of awareness about diseases in some underdeveloped nations has lowered the count of healthcare procedures, thereby inhibiting the development of the market.

medical-specialty-bags-marketIn terms of product, the report segments the market into bile collection bags, anesthesia breathing bags, blood bags, enema bags, enteral feeding bags, continuous ambulatory peritoneal dialysis (CAPD) bags, ostomy collection bags, urinary collection bags, resuscitation bags, intravenous fluid/infusion bags, and others including cadaver bags and ice bags. Ostomy collection bags are further segmented into multi-use ostomy bags and single-use ostomy bags. Ostomy collection bags led the market in 2013 due to the increasing occurrence of chronic diseases such as Ulcerative Colitis and Crohn’s disease, the increasing disposable incomes of consumers, and the rising count of customer awareness programs. On the other hand, by volume, intravenous fluid bags led the market owing to the rising usage of these bags in a number of healthcare procedures. The segment of blood bags is poised to be the most swiftly developing segment in the forecast horizon on the basis of both volume and size owing to the launch of PVC-free blood bags and the increasing occurrence of blood infusion emergencies globally.

By geography, the report segments the market into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, North America led the market in 2013 owing to the increasing presence of reimbursement policies, the rising occurrence of diseases, the mounting adoption of innovative products, and the rise in obesity and related diseases within this region. Asia Pacific, on the other hand, is predicted to emerge as the most promising market in the forecast horizon owing to the robust economic development in nations such as Singapore, the Philippines, China, India, and Australia.

The major players dominant in the market are Coloplast A/S, Hollister Incorporated, Baxter International, Inc., Medline Industries, Inc., Nolato AB, and Macopharma SA, among others.

Full Research Report on Global Medical Specialty Bags Market:
http://www.transparencymarketresearch.com/medical-specialty-bags-market.html

Monday, 14 December 2015

Use of Peptide Therapeutics in Treatment of Diverse Medical Conditions Stimulates Market Growth

According to a new market study released by Transparency Market Research (TMR), the global peptide therapeutics market will be valued at US$23.7 bn by 2020, increasing from its 2013 valuation of US$18.9 bn. If the projected figure hold true, the market will rise at a moderate 2.8% CAGR from 2014 to 2020. The report is titled “Peptide Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020” and is available for sale on the company website.
Browse the full  Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020 report at http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
Therapeutic peptides have received acceptance in the treatment of several diseases such as metabolic disorders, cancer, nervous system disorders, gastrointestinal disorders, acromegaly, hematological disorders, cardiovascular disorders, infections, and respiratory disorders, among others. Due to the efficacy of peptides for the treatment of a large number of medical conditions, further research and development has resulted in a rich pipeline of novel peptides that deliver better therapeutic effects.
Though animal sources such as venom constitute the major source for peptide research, microbial sources are also being examined for their efficacy for treatment of various medical conditions. The growing variety of sources as well as applications of peptide therapeutics is boosting growth prospects of the global peptide therapeutics market. However, despite extensive research, oral administering of therapeutic peptides still remains a challenge for researchers, which is indirectly hampering the peptide therapeutics market. Unfavorable physiological conditions such as the presence of proteolytic enzymes and acidic pH pose a challenge for oral administering of peptide therapeutics. Moreover, low intestinal penetrability of peptides also adds to the low bioavailability of these substances.
Lately, a strong trend has been observed in the peptide therapeutics market: whilst new peptide therapeutic drugs receive regulatory permission, several older peptide therapeutic drugs will go off-patent during the forecast period. In addition, difficulties associated with imitating the precise effects of biologics are a major reason for generic drug manufacturers to face drug approval issues. Thus, generic peptide therapeutic drugs are priced only 70-80% as much as branded peptide therapeutics. Due to this price gap, high demand for generic versions is expected to help the peptide therapeutics market overcome its restraints.
Presently, the generic peptide therapeutic leuprolide is retailed under the brand names Eligard, Lupron, and Enantone, of which Lupron and Enantone constitute sales over US$800 mn across the world.On the competitive front, currently, Teva Pharmaceutical Industries Ltd., Novo Nordisk, and Takeda Pharmaceutical Co. Ltd. collectively account for more than 50% of the global peptide therapeutics market. However, the patent expiration of Copaxone in 2014 and Velcade in 2017 will lead to launch of their generic alternatives. Some other prominent players in the global peptide therapeutics market are AstraZeneca plc, Eli Lilly & Co., Merck & Co., Novartis International, and AbbVie Inc.
The global peptide therapeutics market has been segmented as below:
  • Global Peptide Therapeutics Market, by Application
    • Cancer
      • Zoladex (goserelin)
      • Velcade (bortezomib)
      • Lupron/ Enantone/ Eligard (leuprorelin)
      • Others
    • Cardiovascular
      • Angiomax (bivalirudin)
      • Integrilin (eptifibatide)
    • Central Nervous System
      • Copaxone (glatiramer)
    • Metabolic Disorders
      • Victoza (liraglutide)
      • Byetta (exenatide)
      • Others
    • Infection
      • Incivek (telaprevir)
      • Victrelis (boceprevir)
    • Hematological Disorders
      • Firazyr (icatibant)
      • Kalbitor (ecallantide)
    • Gastrointestinal Disorders
      • Gattex (teduglutide)
      • Linzess (linaclotide)
    • Respiratory Disorders
    • Acromegaly
    • Other Applications
  • Global Peptide Therapeutics Market, by Route of Administration
    • Parenteral
    • Oral
  • Global Peptide Therapeutics Market, by Marketing Status
    • Branded
    • Generic
  • Global Peptide Therapeutics Market, by Geography
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.com/

Thursday, 25 June 2015

Hearing Aid Devices has Acted as a Key Factor for The Market Growth

A hearing aid is an electronic device designed to amplify sounds, particularly speech for people with hearing impairments and loss in hearing abilities. A hearing aid consist of a microphone, a loudspeaker, an amplifier and a battery. The microphone picks up the sound, which is made louder with the help of an amplifier so the wearer can hear things more clearly. Hearing aids are incapable of truly correcting a hearing loss but they are an aid to make sounds more accessible. The global hearing aid market has observed an increase in demand as a result of rising geriatric population. Moreover, hearing aid manufactures are involved in developing and evolving new high-tech hearing aids that are more wearable, with enhanced performance and wireless connectivity to electronic devices. 


The increased sales of digital hearing aid devices has acted as a key factor for the market growth. The development of wireless hearing aids are encouraging more people to opt for hearing aids than ever before. In addition, efficient reimbursement schemes in most countries acted positively for hearing aid market. However, some factors limiting the growth of hearing aid market are elderly population with low income and very few reimbursement plans, particularly in emerging markets. Lack of infrastructure and low average selling price can be one of the obstacle for the growth of hearing aid market in under developed regions.

The hearing aid market can be segmented in terms of technology and styles. Hearing aid technologies are of three types namely; conventional analogue, analogue programmable and digital programmable hearing aid technologies. Conventional analogue hearing aids are designed with a particular frequency response setting instructed by the audiologist to the manufacturer. Although, some adjustments can be made but this aid essentially amplifies all types of sounds (noise and speech) in the same way and is the least expensive technology. Analogue programmable hearing aids have a microchip that allows the audiologist to program the aid for different listening environments for different hearing loss profile, speech understanding and tolerance for louder noise. 

Digital programmable hearing aids have all the features of analogue hearing aids but they are more digitized. Digital hearing aids are self-adjusting, flexible in programming and matches specific hearing loss patterns. Digital hearing aids have key benefits such as longer life span, noise reduction, better fitting, improved programmability, wireless and bluetooth connectivity making them slightly expensive and the most demanded hearing aids. The common styles of hearing aids can be divided into behind-the-ear instruments and in-the-ear instruments. The in-the-ear instruments consist of a completely-in-the-canal (CIC) hearing aid that is molded to fit inside the wearer’s ear canal. It is smallest and least visible type and are in most demand. An in-the-canal (ITC) hearing aid is custom molded and fits partly in the ear canal. It is less visible in the ear than larger styles. An in-the-ear (ITE) hearing aid is custom made that fits within the outer portion the ear. 

It is helpful for people with mild to severe hearing loss. The most appropriate for people of all ages and those with almost any type of hearing loss is the behind-the-ear (BTE) hearing aid that needs to be hooked over the top of the ear and rests behind the ear. A tube connects the hearing aid to a custom earpiece called an ear mold that fits in ear canal. The receiver-in-canal (RIC) and receiver-in-the-ear (RITE) styles are similar to a behind-the-ear hearing aid with the speaker or receiver in the canal or in the ear. A tiny wire, rather than tubing, connects the hearing aid to the ear mold. Overall, it was observed that behind-the-ear hearing aids dominated the hearing aid market in terms of share.

Geographically, Europe is the largest hearing aid market in the world followed by North America. Presence of large number of geriatric population across the developed countries of Western Europe and patients holding relatively higher purchasing powers is one of the primary factor attributing to its large share. The large population of the U.S. are baby boomers, a generation which is considered the wealthiest and healthiest to that time as they were amongst the first generation of population to get exposed to technologies and economic opportunities. The generation’s oldest population is over 65 years of age and thus have entered the target zone of hearing aid industry. This group is tech savvy and health conscious. This is a vital opportunity for the significant growth of hearing aid market as well as portable medical devices market. Majority of hearing aids are sold in the developed markets, while emerging markets have currently low penetration but high market potential in the near future. Both India and China possess the most attractive healthcare market business because of being the world’s most populated countries resulting in large patient pool. Brazil and Mexico were observed as the most potential countries in rest of the world hearing aid market due to rising disposable income, developing healthcare infrastructure and growing economy.

Some of the major players in the global hearing aid market include Sonova Holding AG, William Demant Holding A/S, GN Resound, Widex A/S, Siemens Healthcare AG, and Starkey Hearing Technologies. The other vendors in the market are GN ReSound, Panasonic Corp., Amplifon SpA, MED-EL GmbH, and Zounds Hearing Inc. 

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

  • North America 
  • Asia Pacific 
  • Europe
  • Middle East and Africa
  • Latin America

This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.   

About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Monday, 23 March 2015

Power Banks Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

A portable charger used to charge a wide range of digital product is called power bank. Power bank is also called battery charger. It is used as back-up charger, an external battery or plug-in charger for charging battery cells or rechargeable battery. Power bank is a suitable way to charge electronic device whenever and wherever needed. Mobile devices, digital cameras, laptops and tablets can be charged using power bank. The power bank is designed on the basis of device being charged. Power bank can be re-used and recharged. Milliampere-hour is the measuring unit for the capacity of power bank. Higher Milliampere results in the higher storing capacity of power banks. 

Browse Full Report with TOC:

Power bank comprise of lithium batteries as they are affordable, compact in nature and widely available. A power bank is different from each other even though the battery capacity is exactly the same; in terms of compatibility, pricing, cell quality, internal design, size and cell grade. Power bank batteries are categorized as cylindrical battery, square aluminum case and polymer battery. Due to the high mechanized cost for battery cell made of Lithium-Polymer comparing it to Lithium-Ion, the price of power bank made of Lithium-Polymer battery is higher than the power bank comprise with Lithium-Ion battery. Casing made from standard shell offer protection from any leakage or harm from the power bank. A power bank in general will require 5V/1A for optimum charging period across the globe. Power bank quality, cell PCB board design, actual capacity and reliability are factors determining approximately device charge per cycle.


Mobility and versatility are the most important features of power bank. Power bank are available in various sizes, shapes, capacities and colors. Global power bank market can be segmented on the basis of application and product type. Mobile phone chargers and Electric vehicle chargers are segments of applications. Solar power bank, power bank with LED and built-in rechargeable line are segments of power bank products.

Improved living standards, increased consumer purchasing power and rising economies are uplifting electronics market. The demand for power bank rises as electronic devices comes with low battery capacity. Longer duration usage of smart phone, increased demand of smart phone and increased usage of tablets has spurred the market growth of power bank globally. Functionality of electronic devices are increasing, propelling power bank market. Smart phone battery life has been a problem for consumer. This constraint has become opportunity for power bank companies. Safety is a concern as low grade power cells can be volatile based if overcharged in case of lithium-ion battery.

China is the important player in the power bank market, increasing demand across the world is increasing opportunities globally. Cell phones are sweeping the developing world as the technology become cheap. Growth of power bank market will increasingly rely on emerging market as Western Europe, Japan and North America reach saturation. Power bank is expected to attain success in developing nation where the power grid is lacking.

Some of the global players in power bank market are BYD Battery Company Limited, Energizer Holding INC, LG Chem Power Inc., Philips, Sony Corporation, Lishen, Buffalo Technology, Samsung Electronics, Ultralife Corporation and Sanyo among others. Research & developments and innovations are adopted by the companies as the strategies to rise in the power bank market.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World

This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Technology & Media Market:


About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Inquiry Before Buying @ 



Contact Us

Mr. Atil Chaudhari
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: +1-518-618-1030


Browse market research blog: